LAVA Therapeutics N.V.
Biotechnology-Research
Website
Company Tagline
Developing next generation bispecific gamma-delta T cell engaging (bsTCE) antibodies to fight cancer
Industry Category
Business Keywords
Company Description
LAVA Therapeutics N.V. is a pioneering biotechnology research company focused on transforming cancer therapy through its expertise in gamma-delta T-cell engagers (TCEs). LAVA Therapeutics is dedicated to developing next-generation bispecific gamma-delta T cell engaging (bsTCE) antibodies to fight cancer. Their innovative platform generates therapeutics that specifically activate the Vγ9Vδ2 T-cell subset, triggering immune cell activity in both the innate and adaptive immune systems.
LAVA Therapeutics' gamma-delta bsTCEs have demonstrated impressive efficacy and safety profiles in preclinical studies, showing preferential activity against tumor cells, which potentially limits toxicity in healthy tissue. The company is building a robust pipeline of gamma-delta bsTCEs applicable in both solid and hematologic malignancies. Their lead program, LAVA-051, targets the tumor-specific antigen CD1d, overexpressed in multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML), among other tumor types. LAVA-051 is advancing into a Phase I/IIa study.
Located at Yalelaan 60, 5th floor, Utrecht, Utrecht 3584 CM, NL (Primary Address) and 2929 Arch St, Philadelphia, PA 19104-2857, US, LAVA Therapeutics is committed to advancing the field of oncology. We invite the manager of LAVA Therapeutics N.V. to create a customized and exclusive company showcase and product listing on our platform.
LAVA Therapeutics N.V. est une entreprise de recherche biotechnologique pionnière axée sur la transformation de la thérapie contre le cancer grâce à son expertise dans les activateurs de lymphocytes T gamma-delta (TCE). LAVA Therapeutics se consacre au développement d'anticorps bispécifiques d'activation des lymphocytes T gamma-delta (bsTCE) de nouvelle génération pour lutter contre le cancer. Sa plateforme innovante génère des produits thérapeutiques qui activent spécifiquement le sous-ensemble de lymphocytes T Vγ9Vδ2, déclenchant l'activité des cellules immunitaires dans les systèmes immunitaires innés et adaptatifs.
Les bsTCE gamma-delta de LAVA Therapeutics ont démontré des profils d'efficacité et de sécurité impressionnants dans les études précliniques, montrant une activité préférentielle contre les cellules tumorales, ce qui limite potentiellement la toxicité dans les tissus sains. La société construit un pipeline robuste de bsTCE gamma-delta applicables dans les malignités solides et hématologiques. Son programme phare, LAVA-051, cible l'antigène CD1d spécifique à la tumeur, surexprimé dans le myélome multiple, la leucémie lymphoïde chronique (LLC) et la leucémie myéloïde aiguë (LMA), entre autres types de tumeurs. LAVA-051 progresse vers une étude de phase I/IIa.
Située à Yalelaan 60, 5ème étage, Utrecht, Utrecht 3584 CM, NL (adresse principale) et 2929 Arch St, Philadelphie, PA 19104-2857, US, LAVA Therapeutics s'engage à faire progresser le domaine de l'oncologie. Nous invitons le responsable de LAVA Therapeutics N.V. à créer une vitrine d'entreprise et une liste de produits personnalisées et exclusives sur notre plateforme.
Key Personnel / Employees
Compare Companies Side by Side
Compare LAVA Therapeutics N.V. with 3 companies in Biotechnology-Research
| Comparison Field |
LAVA Therapeutics N.V.Main Company |
Facet BiotechView Profile |
Allogene Therapeutic...View Profile |
Mestag TherapeuticsView Profile |
|---|---|---|---|---|
|
Founded Year
|
— | 2008 | 2017 | 2020 |
|
Company Size
|
— | 51-200 | 201-500 | 11-50 |
|
City
|
Utrecht, Utrecht | South San Francisco, California | ||
|
Country
|
Netherlands | United States | ||
|
Skills & Keywords
Comparing with main company
|
11 Total Skills
Biotechnology
Oncology
Gamma-delta T cells
Bispecific antibodies
Cancer therapy
Immunotherapy
Hematologic malignancies
oncology
biotechnology
gamma delta T cells
bispecific antibodies
|
2 Total
2 Unique
Unique Skills:
antibody engineering
immunology
|
4 Total
4 Unique
Unique Skills:
autoimmune
cancer
CAR T
immunotherapy
|
4 Total
4 Unique
Unique Skills:
datascience
fibroblasts
immuno oncology
inflammatory disease
|
4
Total Companies2008
Oldest Founded2
Countries21
Unique SkillsSimilar Companies
Other organizations in the same industry
Gritstone bio
Biotechnology-ResearchA lean biotech company aiming to develop revolutionary immune-based treatment for various cancers.
VBI Vaccines Inc.
Biotechnology-ResearchDriven by Immunology in the Pursuit of Powerful Prevention and Treatment of Disease
MindTrace
Biotechnology-ResearchDeveloping neurosurgical software to protect patients’ minds.
Alternative Company Names
This company is also known as